Clinical trials
Macular Degeneration clinical trials
Below are recruiting macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 168 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05675150Recruiting
Art-based program for adults with age-related vision loss
This trial tests whether an expressive arts-based program can help adults who have age-related macular degeneration (a common cause of vision loss) by supporting wellbeing and daily functioning. If you meet the language, vision, and health requirements, participating may help you benefit from a structured arts intervention.
Hong KongAges 50–80 - NCT05913063Recruiting
Testing how the eye responds to tiny quantum states
This study looks at how the human eye detects very small “quantum” information. It compares people with certain vision conditions to people with normal vision to see how the eye’s macula and overall vision are involved.
Hong Kong, GuangdongAges 18 years+ - NCT05932069Recruiting
Exercise program for intermediate age-related eye disease
This study tests whether an active (aerobic) exercise program can improve day-to-day function in Veterans with intermediate age-related macular degeneration (AMD). To join, you must have the right type stage of AMD, be able to do the assessments and exercise, and meet health and internet needs.
Decatur, GeorgiaAges 65–89 - NCT05959005Recruiting
Tracking early macular atrophy changes in the eye
This study focuses on people age 50+ with early “wasting away” changes in the macula (central retina) called atrophic lesions. It aims to better understand how these early changes progress and how they affect vision testing, which may help improve future treatments.
Salt Lake City, UtahAges 50 years+ - NCT06074731Recruiting
Eye imaging study using a new scanner
This trial uses a special eye scanner to look at eye diseases. It might help doctors see eye problems more clearly.
Linz, Upper AustriaAges 5–110 - NCT06271330Recruiting
Switching older injections to faricimab for wet AMD
This study looks at people with wet AMD who have been getting regular eye injections of either aflibercept or ranibizumab for over a year. The goal is to see what happens when they switch to a newer injection called faricimab.
Nantes, NantesAges 18 years+ - NCT06346600Recruiting
Long-term follow-up for SKG0106 in wet AMD
This study follows people who already received the SKG0106 injection in a previous trial for wet age-related macular degeneration (nAMD). It checks how they are doing over a longer period.
Boston, MassachusettsAges 50 years+ - NCT06445322Recruiting
Finding people with Stargardt disease for ACDN-01
This prescreening study looks for people with a specific genetic eye condition called Stargardt disease to see if they might be able to join a future trial for a new treatment called ACDN-01.
San Francisco, CaliforniaAges 5 years+ - NCT06467344RecruitingPhase 1/Phase 2
Testing ACDN-01 for ABCA4 Stargardt eye disease
This trial tests an experimental medicine called ACDN-01 for people with Stargardt retinopathy caused by ABCA4 gene mutations. The goal is to see if it can slow or stop vision loss in an eye with already damaged central vision.
San Francisco, CaliforniaAges 12 years+ - NCT06489873Recruiting
Lutein, Zeaxanthin, and Fish Oil for Macular Health
This study tests whether taking daily supplements of lutein, zeaxanthin, and fish oil can improve the protective pigment in your eyes. It may help people with low macular pigment and good vision who are not already taking high doses of these nutrients.
College Station, TexasAges 18–45 - NCT06557460RecruitingPhase 2
Cell implant for advanced dry age-related macular degeneration
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
Beverly Hills, CaliforniaAges 55–90 - NCT06593405RecruitingEarly Phase 1
Occupational therapy for eye disease medication management
This trial tests whether occupational therapy can help people with age-related macular degeneration (AMD), diabetic retinopathy (DR), or glaucoma better manage their medications. Participants share their deidentified data to see if therapy improves outcomes.
Worcester, MassachusettsAges 50–100 - NCT03848663Recruiting
Training with visual remapping to help reading with central vision loss
This study tests whether a computer-based visual training method (“remapping”) can help people read better even when they have reduced central vision. You may benefit if your eye condition is stable and your eyes can reliably track the training on an eye-tracker.
Minneapolis, MinnesotaAges 16 years+ - NCT06604104Recruiting
Visual Frailty Study in Older Adults with AMD
This study looks at something called 'visual frailty' in older adults with advanced age-related macular degeneration (AMD). It aims to develop a tool to better understand how vision loss affects daily life and overall health in people aged 60 and over.
Edinburgh, ScotlandAges 60 years+ - NCT06779773Recruiting
Study of avacincaptad pegol (Izervay) for geographic atrophy
This study looks at how avacincaptad pegol (brand name Izervay) works in real-world medical practice for people with geographic atrophy, a form of age-related macular degeneration that causes vision loss. If your doctor has already decided to treat you with this medicine, you may be able to join.
Phoenix, ArizonaAges Any age - NCT06787482RecruitingPhase 1/Phase 2
Peptide therapy for retinitis pigmentosa
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
CairoAges Any age - NCT06805474Recruiting
Study of a vision test for Stargardt and geographic atrophy
This study tests a new way to measure vision, called MLSDT, in people with normal sight or vision loss from Stargardt disease or geographic atrophy (a type of advanced age-related macular degeneration). Results will help doctors better understand how well patients can see.
Dallas, TexasAges 18 years+ - NCT06843499Recruiting
AI eye screening for AMD and diabetic retinopathy
This trial tests an AI program called VeriSee that helps doctors check for eye problems like age-related macular degeneration (AMD) and diabetic retinopathy (DR). It compares the AI's accuracy and costs to standard care in regular eye clinics.
Taipei, TaiwanAges 20 years+ - NCT06875245RecruitingPhase 4
Comparing 8-Week vs 12-Week Faricimab for Wet AMD
This trial compares two different schedules (8 weeks vs 12 weeks) for follow-up injections of faricimab in people who are starting treatment for wet AMD. It aims to see if a longer gap between doses works just as well as the shorter interval.
PragueAges Any age - NCT06906003Recruiting
Vision rehab and depression in age-related macular degeneration
This trial tests whether visual rehabilitation can help improve both vision and mood in people with advanced dry age-related macular degeneration. It aims to understand the link between vision loss and depression.
Rome, ItalyAges 55 years+ - NCT06943599Recruiting
Improving Eye Care After Screening
This study looks at better ways to help people get follow-up eye care after a screening. If you were in the VIEW II study and were referred to an eye hospital, this trial may offer strategies to support you in getting that care.
San Francisco, CaliforniaAges 60 years+ - NCT07004361Recruiting
Ethics of gene therapy for wet AMD
This study explores the ethical questions around using gene therapy for wet age-related macular degeneration (AMD). It is not a treatment trial, but a discussion study for patients whose doctors might consider gene therapy as an option.
Nantes, NantesAges 18 years+ - NCT07015034Recruiting
Preventing vision loss in older adults with chronic conditions
This study tests a model to help general practitioners find older patients who may be at risk of vision loss. It aims to spot problems early so treatment can start sooner.
Copenhagen, Capital RegionAges 70 years+ - NCT07085533Recruiting
A Study of Inherited Retinal Diseases
This study is looking at how inherited retinal diseases affect color vision over time. It may help researchers understand these conditions better and is a good fit for people with a known diagnosis who can describe what they see.
WuhanAges Any age
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for macular degeneration?
- Yes. Clin2 currently lists 168 recruiting macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.